Drug intelligence / Profile preview

salmonella typhimurium expressing INHA miRNA

Development stage: Unknown
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Subcutaneous

Overview

This drug is a **genetically engineered, attenuated Salmonella Typhimurium** (specifically the BRD509 strain, an aroA aroD mutant) expressing a microRNA targeting the **INHA gene**, which is implicated in radiation resistance and cancer growth, particularly melanoma. The therapy acts by delivering INHA miRNA to tumor cells through bacterial infection, resulting in **downregulation of INHA**, increased production of reactive oxygen species (ROS), decreased anti-apoptotic Bcl-2 levels, and induction of apoptosis in cancer cells. Studies show enhanced anti-cancer efficacy when combined with radiotherapy, especially against radiation-resistant tumors. This product is experimental and has been developed and tested for radioresistant melanoma models in vivo, where it reduced tumor growth and improved survival rates in mice. The bacteria are cleared from tissues within days post-administration, especially when combined with radiation, and the treatment promotes increased IFN-γ secretion in animals[1][2].

Other names: S. Typhimurium BRD509 expressing INHA miRNA

Targets

TGFβ ligands (TGF-β ligand superfamily)

Beyond the preview

Go deeper on salmonella typhimurium expressing INHA miRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on salmonella typhimurium expressing INHA miRNA.

Explore the full profile